arrow
Return

Does Gabapentin Use Following ACDF Decrease Opioid Utilization? A Retrospective Propensity-Matched Analysis Conducted in Academic Medical Centers

delete2026-03-20
delete0
delete
OA
AI
M
Mark A. Miller
H
Hunter Jackson Smith
O
Omar Sbaih
M
Matthew Meade
R
Ruchir Nanavati
N
Nithin Gupta
W
William T. DiCiurcio
G
Gregory Schroeder
C
Christopher Kepler
B
Barrett Woods
DOI:10.1177/21925682261438475delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
<jats:sec> <jats:title>Study Design</jats:title> <jats:p>Retrospective Propensity-Matched Analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Objectives</jats:title> <jats:p>Optimal control of postoperative pain while minimizing opioid consumption is paramount in spine surgery. While gabapentinoids have robust utilization for the treatment of neuropathic pain and neuroprotective effects, their interplay in multimodal analgesia following ACDF is unclear. The objective of the present study was to investigate the association between postoperative gabapentinoid use and postoperative opioid use following ACDF.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We conducted a retrospective cohort study using the TriNetX Research network, identifying adult patients who underwent ACDF between 2003-2023. Patients with chronic opioid use were excluded. After 1:1 propensity score matching, cohorts were constructed based on receipt of postoperative gabapentinoids vs acetaminophen monotherapy. Outcomes included opioid utilization and surgical/systemic complications across standardized follow-up intervals (30 days, 90 days, 6 months, 1 year, 2 years, and 5 years). Risk ratios with 95% confidence intervals were calculated, and Kaplan-Meier analyses assessed time-to-event outcomes.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p> After matching, 32 455 patients were included in each group. Gabapentinoid use was associated with higher opioid consumption at every interval, persisting through 5 years (2.29% vs 0.51% at 5 years, RR 4.61, <jats:italic toggle="yes">P</jats:italic> &lt; 0.001). Gabapentinoid recipients had a greater risk of pneumonia and respiratory failure across multiple timepoints. Kaplan-Meier curves demonstrated durable separation between groups for pneumonia, respiratory failure, and opioid use (all log-rank <jats:italic toggle="yes">P</jats:italic> &lt; 0.001). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Gabapentinoids use following ACDF was associated with increased opioid utilization and higher complication rates, challenging their presumed benefit in this setting. These findings suggest that gabapentinoids may not be an effective adjunct in multimodal pain regimens for ACDF.</jats:p> </jats:sec>
Keywords:
ACDF
gabapentinoids
opioid utilization
multimodal analgesia
postoperative pain

Journal

Global Spine Journal cover
Global Spine Journal
IF:
3
Papers:
824
Citations:
6.1K

Organization

G
georgetown university
Scholars:
292
Papers: 153
Citations: 0
N
new england baptist hospital
Scholars:
3
Papers: 4
Citations: 0
J
jefferson health
Scholars:
24
Papers: 12
Citations: 0
R
rothman orthopedic institute
Scholars:
10
Papers: 4
Citations: 0
researcher View more organizations